Manufacturer record
Apple Formulation Pvt. Ltd: regulatory record
Last checked 20 September 2026. Source: CDSCO monthly NSQ alerts and state drug-testing laboratories
4 batches manufactured by Apple Formulation Pvt. Ltd (Uttarakhand) were declared Not of Standard Quality between July 2022 and February 2025. Records are batch-specific findings by government laboratories as published in CDSCO's monthly alerts; where a company has stated that a flagged batch was counterfeit, that statement is noted when reported.
Records by type
4 records linked to Apple Formulation Pvt. Ltd in the datasets we hold. A zero means nothing is on record in those datasets, not that nothing ever happened. What the labels mean.
CDSCO drug alerts: Not of Standard Quality and spurious drugs
Scope. A company appearing here is not a finding that its products are unsafe. Regulatory actions can apply to one batch, one formulation, one period or one state. Always check the linked government document for the current position, and tell us if something is out of date. How we label records.
Flagged batches per year
All flagged batches
| Product | Batch | Reason declared NSQ | Tested by | Alert |
|---|---|---|---|---|
| Vitamin B1, Vitamin B2, Nicotinamide, Vitamin B6, Vitamin B12 & Calcium D-Pantothenate Syrup (B- Complex Syrup) | BOB-2452Mfg 2024-06 · Exp 2025-11 | Assay of Vitamin B12Assay | CDL KolkataCDSCO lab | Feb 2025 |
| Rabeprazole Sodium (Enteric Coated) and Domperidone (Sustained Release) Capsules (20 mg/30 mg) | RPE-2285Mfg 2022-08 · Exp 2024-07 | Assay of Rabeprazole SodiumAssay | RDTL ChandigarhCDSCO lab | Oct 2023 |
| Methodol -16 (Methylpredinisolone Tablets I.P.) | MHD2201Mfg 2022-02 · Exp 2024-01 | DissolutionDissolution | CDL KolkataCDSCO lab | Nov 2022 |
| Levocetirizine Dihydrochloride Tablets IP 5 mg | LCL-2105Mfg 2021-07 · Exp 2023-06 | DissolutionDissolution | RDTL GuwahatiState lab | Jul 2022 |
Right of reply. Manufacturers may submit a response or a laboratory re-test result; it is published unedited alongside this record. Submit a response.